266 related articles for article (PubMed ID: 33096896)
21. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
Ruff MW; Mauermann ML
Neurologist; 2018 May; 23(3):98-99. PubMed ID: 29722744
[TBL] [Abstract][Full Text] [Related]
22. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis.
Tavakoli Dargani Z; Singla DK
Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H460-H471. PubMed ID: 31172809
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
24. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
[TBL] [Abstract][Full Text] [Related]
25. Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor.
Jhuo SJ; Liu IH; Tsai WC; Chou TW; Lin YH; Wu BN; Lee KT; Lai WT
Molecules; 2020 Aug; 25(16):. PubMed ID: 32784369
[TBL] [Abstract][Full Text] [Related]
26. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study.
Goh W; Sleptsova-Freidrich I; Petrovic N
J Pharm Pharm Sci; 2014; 17(3):439-46. PubMed ID: 25224353
[TBL] [Abstract][Full Text] [Related]
27. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications.
Vaziri Z; Saleki K; Aram C; Alijanizadeh P; Pourahmad R; Azadmehr A; Ziaei N
Biomed Pharmacother; 2023 Dec; 168():115686. PubMed ID: 37839109
[TBL] [Abstract][Full Text] [Related]
28. Lipopolysaccharide (LPS) Aggravates High Glucose- and Hypoxia/Reoxygenation-Induced Injury through Activating ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis in H9C2 Cardiomyocytes.
Qiu Z; He Y; Ming H; Lei S; Leng Y; Xia ZY
J Diabetes Res; 2019; 2019():8151836. PubMed ID: 30911553
[TBL] [Abstract][Full Text] [Related]
29. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
30. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC; Rozeman EA; Kapiteijn EH; Verdegaal EME; Grummels A; Bakker JA; Huizinga TWJ; Haanen JB; Toes REM; van der Woude D
Cancer Immunol Res; 2019 Jan; 7(1):6-11. PubMed ID: 30425107
[TBL] [Abstract][Full Text] [Related]
31. Cardiorenal complications of immune checkpoint inhibitors.
Sury K; Perazella MA; Shirali AC
Nat Rev Nephrol; 2018 Sep; 14(9):571-588. PubMed ID: 30013100
[TBL] [Abstract][Full Text] [Related]
32. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
33. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology.
Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T
J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546
[No Abstract] [Full Text] [Related]
34. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2.
Zhou Y; Fan J; Zheng C; Yin P; Wu H; Li X; Luo N; Yu X; Chen C
Biomed Pharmacother; 2019 Jan; 109():1327-1338. PubMed ID: 30551383
[TBL] [Abstract][Full Text] [Related]
35. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
[TBL] [Abstract][Full Text] [Related]
36. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
37. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumorigenic effects of a novel digitoxin derivative on both estrogen receptor-positive and triple-negative breast cancer cells.
Kulkarni YM; Yakisich JS; Azad N; Venkatadri R; Kaushik V; O'Doherty G; Iyer AKV
Tumour Biol; 2017 Jun; 39(6):1010428317705331. PubMed ID: 28618929
[TBL] [Abstract][Full Text] [Related]
39. Empagliflozin directly improves diastolic function in human heart failure.
Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
[TBL] [Abstract][Full Text] [Related]
40. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma.
Liu Y; Liu Z; Zeng X; Bai C; Chen L; Lin S; Tian X
BMC Cancer; 2019 Dec; 19(1):1193. PubMed ID: 31805889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
